

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

OTHER RELEVANT INFORMATION

As a continuation of the Other Relevant Information communication ("**OIR**") filed by Grifols on 27 September 2021, Grifols informs that today it has closed the issuance of its Senior Unsecured Notes in the equivalent amount of EUR 2 billion to finance its investment in Biotest AG, as reported in the Inside Information communication dated 17 September 2021 and OIR communication dated 27 September 2021 (the "**Prior Communications**").

The issuance has been divided into two tranches: a tranche of EUR 1.4 billion and a coupon of 3.875% and a tranche in US dollars, equivalent to EUR 600 million, and a coupon of 4.750%. In both cases with a 7 year maturity (until October 2028).

As explained in the Prior Communications, the proceeds will be used to finance the EUR 1.1 billion acquisition of the entire share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, which owns 89.88% of the ordinary shares, and 1.08% of the preferred shares of Biotest AG.

Additionally, these funds will be used to finance the voluntary public tender offer for the remaining ordinary and preferred shares of Biotest AG.

BofA Securities has acted as sole underwriter and sole bookrunner for the issuance.

In Barcelona, on 5 October 2021

Nuria Martín Barnés
Secretary to the Board of Directors